Sign In
Buy CRSP
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
04:00pm, Wednesday, 08'th May 2024
-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected-
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
07:00am, Wednesday, 08'th May 2024
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma -
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
12:00pm, Saturday, 04'th May 2024
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untr
CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know
06:56pm, Friday, 03'rd May 2024
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $55.89, indicating a +1.49% shift from the previous trading day.
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar
02:18pm, Friday, 03'rd May 2024
Gene editing stocks are among the most intriguing in the biotech scene. The genomics revolution may be as exciting as the ongoing artificial intelligence one.
Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
11:30am, Friday, 03'rd May 2024
Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
07:15am, Thursday, 02'nd May 2024
CRISPR Therapeutics, Regeneron, and Sanofi all deserve a close look now. These three biotechs have important growth drivers on the market.
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
11:59am, Wednesday, 01'st May 2024
While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of reces
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
10:01am, Wednesday, 01'st May 2024
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
01:25pm, Tuesday, 30'th Apr 2024
CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 th
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
06:56pm, Friday, 26'th Apr 2024
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.91, moving +0.34% from the previous trading session.
Crispr Therapeutics: Now Is The Time To Buy
12:40pm, Wednesday, 24'th Apr 2024
Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases pr
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
07:06pm, Monday, 22'nd Apr 2024
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.02, representing a -0.05% change from its previous close.
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
04:30pm, Monday, 22'nd Apr 2024
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dis
Bullish Trendline Has Never Failed Crispr Therapeutics Stock
12:58pm, Wednesday, 17'th Apr 2024
Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of $91.10.
